Adenosine A2A Receptor Activation Enhances Blood–Tumor Barrier Permeability in a Rodent Glioma Model

The blood–tumor barrier (BTB) limits the entry of effective chemotherapeutic agents into the brain for treatment of malignant tumors like glioblastoma. Poor drug entry across the BTB allows infiltrative glioma stem cells to evade therapy and develop treatment resistance. Regadenoson, an FDA-approved...

Descripción completa

Detalles Bibliográficos
Autores principales: Vézina, Amélie, Manglani, Monica, Morris, DreeAnna, Foster, Brandon, McCord, Matthew, Song, Hua, Zhang, Meili, Davis, Dionne, Zhang, Wei, Bills, Jessica, Nagashima, Kunio, Shankarappa, Priya, Kindrick, Jessica, Walbridge, Stuart, Peer, Cody J., Figg, William D., Gilbert, Mark R., McGavern, Dorian B., Muldoon, Leslie L., Jackson, Sadhana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
Signal Transduction and Functional Imaging
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642293/
https://www.ncbi.nlm.nih.gov/pubmed/34521765
http://dx.doi.org/10.1158/1541-7786.MCR-19-0995

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642293/
https://www.ncbi.nlm.nih.gov/pubmed/34521765
http://dx.doi.org/10.1158/1541-7786.MCR-19-0995

Ejemplares similares